CIBC Bancorp USA’s Haemonetics HAE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$570K Buy
5,402
+1,933
+56% +$180K ﹤0.01% 1295
2026
Q2
$260K Buy
+3,469
New +$223K ﹤0.01% 1628
2025
Q3
$251K Buy
+5,140
New +$318K ﹤0.01% 1161

Other funds holding HAE

CIBC Bancorp USA's HAE Position: Q3 2026 in Review

CIBC Bancorp USA increased its Haemonetics (HAE) stake by 56% in Q3 2026, buying an estimated $180K and bringing the position to 5,402 shares worth $570K. The position accounts for ﹤0.01% of the portfolio, ranked #1295.

CIBC Bancorp USA first reported a position in HAE in Q3 2025 and has held it in 3 quarters since. 302 funds tracked by Wall St. Rank hold HAE as of Q3 2026.

  • CIBC Bancorp USA held 5,402 shares of Haemonetics worth $570K as of Q3 2026.
  • CIBC Bancorp USA bought 1,933 Haemonetics shares in Q3 2026, an estimated $180K.
  • Haemonetics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1295 holding.
  • CIBC Bancorp USA first reported a position in Haemonetics in Q3 2025 and has held it in 3 quarters since.
  • 302 funds tracked by Wall St. Rank held Haemonetics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.